TY - JOUR T1 - Prevalence of hereditary tubulointerstitial kidney diseases in the German Chronic Kidney Disease study JF - medRxiv DO - 10.1101/2021.09.29.21264100 SP - 2021.09.29.21264100 AU - Bernt Popp AU - Arif B. Ekici AU - Karl X. Knaup AU - Karen Schneider AU - Steffen Uebe AU - Jonghun Park AU - Vineet Bafna AU - Heike Meiselbach AU - Kai-Uwe Eckardt AU - Mario Schiffer AU - André Reis AU - Cornelia Kraus AU - Michael Wiesener Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/30/2021.09.29.21264100.abstract N2 - Exome sequencing (ES) studies in chronic kidney disease (CKD) cohorts could identify pathogenic variants in ∼10% of patients. This implies underdiagnosis of hereditary CKD. Tubulointerstitial kidney diseases, showing no typical clinical/histologic finding but tubulointerstitial fibrosis, are particularly difficult to diagnose.We used a custom designed targeted panel (29 genes) and MUC1-SNaPshot to sequence 271 DNA samples, selected by clinical criteria from 5,217 individuals in the German Chronic Kidney Disease (GCKD) cohort.We identified 33 pathogenic small variants. Of these 27 (81.8%) were in COL4-genes, the largest group being 15 COL4A5-variants with nine unrelated individuals carrying c.1871G>A, p.(Gly624Asp). We found three cysteine variants in UMOD, a novel missense, and a novel splice variant in HNF1B and the homoplastic MTTF variant m.616T>C. Copy-number analysis identified a heterozygous COL4A5-deletion, and a HNF1B-duplication/-deletion, respectively. Overall, pathogenic variants were present in 12.5% (34/271) and variants of unknown significance in 9.6% (26/271) of selected individuals. Bioinformatic predictions paired with gold standard diagnostics for MUC1 (SNaPshot) could not identify the typical cytosine duplication (“c.428dupC”) in any individual, implying that ADTKD-MUC1 is rare.Our study shows that >10% of individuals with certain clinical features carry disease variants in genes associated with tubulointerstitial kidney diseases. COL4-genes constitute the largest fraction, implying they are overlooked using clinical Alport-syndrome criteria. We also identified variants easily missed by some ES pipelines. Finally, our results indicate that the filtering criteria applied enrich for an underlying genetic disorder.SIGNIFICANCE STATEMENT CKD affects >10% of the global population and recent studies imply that a considerable portion can be attributed to monogenic diseases, which are likely underappreciated in the clinical routine. Tubulointerstitial kidney diseases are a particularly difficult group of hereditary kidney diseases to diagnose both clinically and genetically. To investigate the prevalence of these disorders in a large CKD cohort we established a set of clinical criteria and designed a custom panel sequencing pipeline. Based on the diagnostic yield of 12.5%, we recommend an algorithm to clinically select and genetically evaluate patients with increased risk for a hereditary tubulointerstitial kidney disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe studies were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 387509280 - SFB 1350, TP C4. In addition an unrestricted donation to the Department of Nephrology and Hypertension was used from Fischer Business Technology GmbH in Grasbrunn / Muenchen. Bernt Popp is supported by the Deutsche Forschungsgemeinschaft (DFG) through grant PO2366/2-1. The GCKD study was/is supported by Bundesministerium fuer Bildung und Forschung and Kuratorium fuer Heimdialyse und Nierentransplantation e.V.-Stiftung Praeventivmedizin, and corporate sponsors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study adheres to the principles set out in the Declaration of Helsinki. The probands included in our study were filtered using the database of the German Chronic Kidney Disease (GCKD) cohort which enrolled 5,217 individuals. The GCKD study is registered as a national clinical study (DRKS 00003971) and was approved by local ethics review boards of all participating institutions as published previously (10.1093/ndt/gfr456).The Ethical Committee of the Friedrich-Alexander University (FAU) Erlangen-Nuernberg approved the study protocol ("Prospektive Beobachtungsstudie- German Chronic Kidney Disease (GCKD)-Studie"; Re.-Nr. 3831; decision date: 3.7.2008) representing the GCKD lead center at FAU.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available through Zenodo. https://doi.org/10.5281/zenodo.5516388 ER -